Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | G6PD | P11413 | 1/20 | 0.43 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | AHR | P35869 | 1/20 | 0.43 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.43 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.43 |
| ▸ | UBA2 | Q9UBT2 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | MIF | P14174 | 1/20 | 0.41 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.41 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | TXNRD1 | Q16881 | 2/20 | 0.41 |
| ▸ | TXNRD3 | Q86VQ6 | 2/20 | 0.41 |
| ▸ | TXNRD2 | Q9NNW7 | 2/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | SNCA | P37840 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30059668 | 1.00 | G6PD (0.43) | G6PDTLR9MAPTAHRMCL1 | |
| SCHEMBL25221160 | 0.86 | PHOSPHO1 (0.43) | MAPTTDP1ALDH1A1CYP3A4PDE7A | |
| SCHEMBL10375442 | 0.81 | CYP2A6 (0.57) | G6PDTLR9MAPTTDP1ALDH1A1 | |
| SCHEMBL5256400 | 0.81 | TDP1 (0.50) | G6PDTLR9MAPTTDP1ALDH1A1 | |
| SCHEMBL5338932 | 0.81 | ALDH1A1 (0.52) | G6PDTLR9MAPTTDP1ALDH1A1 | |
| SCHEMBL4263947 | 0.77 | TSHR (0.42) | G6PDTLR9MAPTALDH1A1MIF | |
| SCHEMBL2844302 | 0.77 | ALDH1A1 (0.51) | G6PDTLR9MAPTTDP1ALDH1A1 | |
| SCHEMBL6790964 | 0.76 | KMT2A (0.53) | MAPTTDP1ALDH1A1CYP3A4TSHR | |
| SCHEMBL11118149 | 0.75 | SMN1; SMN2 (0.50) | G6PDTLR9MAPTAHRMCL1 | |
| SCHEMBL23612371 | 0.75 | PTGES (0.50) | G6PDTLR9MAPTTDP1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12612413-B2 | Heteroaryl compounds as inhibitors of programmed necrosis pathway, composition and method using the same | ACCRO BIOSCIENCE (HK) LIMITED (CN) | 2026-04-28 | — | — | US | disclosed |
| EP-4085059-B1 | HETEROARYL COMPOUNDS AS INHIBITORS OF PROGRAMMED NECROSIS PATHWAY, COMPOSITION AND METHOD USING THE SAME | ACCRO BIOSCIENCE HK LTD (HK) | 2024-03-20 | — | — | EP | disclosed |
| US-20230121233-A1 | Heteroaryl compounds as inhibitors of programmed necrosis pathway, composition and method using the same | ACCRO BIOSCIENCE (HK) LIMITED (HK) | 2023-04-20 | — | — | US | disclosed |
| WO-2021138694-A1 | HETEROARYL COMPOUNDS AS INHIBITORS OF PROGRAMMED NECROSIS PATHWAY, COMPOSITION AND METHOD USING THE SAME | ACCRO BIOSCIENCE INC. (KY) | 2021-07-08 | — | — | WO | disclosed |
| US-6767907-B2 | FOR THERAPY OF PSYCHIC AND NEUROLOGIC DISORDERS | H. LUNDBECK A/S (DK) | 2004-07-27 | — | — | US | disclosed |
| US-6743808-B1 | PSYCHOLOGICAL AND NEUROLOGIC DISORDERS; CENTRAL SEROTONERGIC 5-HT1A AND 5-HT2A RECEPTOR ANTAGONISTS | H. LUNDBECK A/S (DK) | 2004-06-01 | — | — | US | disclosed |
| EP-1003738-B1 | BICYCLIC COMPOUNDS AS LIGANDS FOR 5-HT1 RECEPTORS | SMITHKLINE BEECHAM PLC (GB) | 2003-11-19 | — | — | EP | disclosed |
| US-20030195356-A1 | 4-Aryl-1-(indanmethyl dihydrobenzofuranmethyl or dihydrobenzothiophenemethyl) piperidines tetrahydropyridines or piperazines | PERREGAARD JENS KRISTIAN (DK) | 2003-10-16 | — | — | US | disclosed |
| US-6391891-B1 | ANTISEROTONINE AGENT; ANXIOLYTIC AGENTS, ANTIDEPRESSANTS | SMITHKLINE BEECHAM PLC (GB) | 2002-05-21 | — | — | US | disclosed |
| US-6218394-B1 | FOR THERAPY OF SCHIZOPHRENIA, OTHER PSYCHOSES, ANXIETY DISORDERS, SUCH AS GENERALISED ANXIETY DISORDER, PANIC DISORDER | H. LUNDBECK A/S (DK) | 2001-04-17 | — | — | US | disclosed |
| EP-0765311-B1 | 4-ARYL-1-(INDANMETHYL, DIHYDROBENZOFURANMETHYL OR DIHYDROBENZOTHIOPHENEMETHYL)PIPERIDINES, TETRAHYDROPYRIDINES OR PIPERAZINES | LUNDBECK & CO AS H (DK) | 2000-10-04 | — | — | EP | disclosed |
| EP-1003738-A1 | BICYCLIC COMPOUNDS AS LIGANDS FOR 5-HT1 RECEPTORS | SMITHKLINE BEECHAM PLC (GB) | 2000-05-31 | — | — | EP | disclosed |
| WO-1999007700-A1 | BICYCLIC COMPOUNDS AS LIGANDS FOR 5-HT1 RECEPTORS | SMITHKLINE BEECHAM PLC (GB) | 1999-02-18 | — | — | WO | disclosed |
| EP-0765311-A1 | 4-ARYL-1-(INDANMETHYL, DIHYDROBENZOFURANMETHYL OR DIHYDROBENZOTHIOPHENEMETHYL)PIPERIDINES, TETRAHYDROPYRIDINES OR PIPERAZINES | H. LUNDBECK A/S (DK) | 1997-04-02 | — | — | EP | disclosed |
| WO-1995033721-A1 | 4-ARYL-1-(INDANMETHYL, DIHYDROBENZOFURANMETHYL OR DIHYDROBENZOTHIOPHENEMETHYL)PIPERIDINES, TETRAHYDROPYRIDINES OR PIPERAZINES | H. LUNDBECK A/S (DK) | 1995-12-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12612413-B2 | Heteroaryl compounds as inhibitors of programmed necrosis pathway, composition and method using the same | CASP6, CASP3, BAX | G6PD 355/4885TLR9 564/4885MAPT 592/4885 |
| US-20030195356-A1 | 4-Aryl-1-(indanmethyl dihydrobenzofuranmethyl or dihydrobenzothiophenemethyl) piperidines tetrahydropyridines or piperazines | CNR1, TPH1, CNR2 | G6PD 3011/4885TLR9 2294/4885MAPT 2538/4885 |
| US-20230121233-A1 | Heteroaryl compounds as inhibitors of programmed necrosis pathway, composition and method using the same | BAX, PDCD1, PDCD4 | G6PD 433/4885TLR9 766/4885MAPT 1983/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.